Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 213Precursor Cell Lymphoblastic Leukemia-Lymphoma 174Leukemia 163Lymphoma 148Lymphoma, Non-Hodgkin 142Leukemia, Myeloid, Acute 142Myelodysplastic Syndromes 132Hodgkin Disease 123Lymphoma, Follicular 111Lymphoma, Mantle-Cell 108Multiple Myeloma 105Lymphoma, Large B-Cell, Diffuse 96Lymphoma, B-Cell, Marginal Zone 89Burkitt Lymphoma 85Myeloproliferative Disorders 73Leukemia, Myelomonocytic, Chronic 63Congenital Abnormalities 63Leukemia, Myeloid, Chronic-Phase 62Lymphoma, Large-Cell, Immunoblastic 61Leukemia, Myeloid, Accelerated Phase 60Waldenstrom Macroglobulinemia 55Leukemia, Myelogenous, Chronic, BCR-ABL Positive 53Neoplasms, Plasma Cell 52Primary Myelofibrosis 48Recurrence 46Blast Crisis 44Anemia, Refractory, with Excess of Blasts 43Lymphoma, T-Cell, Cutaneous 42Dendritic Cell Sarcoma, Interdigitating 42Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 40

Interventions

siltuximab 2fludarabine phosphate 2fludarabine 2Interleukin 1 Receptor Antagonist Protein 2Cyclophosphamide 2AP 1903 reagent 2obinutuzumab 1glofitamab 1axicabtagene ciloleucel 1Oxaliplatin 1Neuropsychological Tests 1Magnetic Resonance Spectroscopy 1Gemcitabine 1Gelsolin 1Contrast Media 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cytokine Release Syndrome × fludarabine phosphate × Lymphoid × Clear all
NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

UNC Lineberger Comprehensive Cancer Center

Phase 1 Active not recruiting
19 enrolled
Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡